Stock Information

• Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript
  Thu, Apr 2, 2026 4:32 PM
• Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update - Slideshow
  Thu, Apr 2, 2026 1:42 PM
• Alto Neuroscience, Immunovant And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
  Thu, Apr 2, 2026 8:02 AM
• Market-Moving News for April 2nd
  Thu, Apr 2, 2026 7:17 AM
• Immunovant shares are trading lower after the company announced topline results from its two Phase 3 clinical studies evaluating batoclimab for adults with active, moderate-to-severe thyroid eye disease. The studies failed to meet their primary endpoint.
  Thu, Apr 2, 2026 6:51 AM
• Why Globalstar Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
  Thu, Apr 2, 2026 5:10 AM
• Immunovant's Phase 3 Batoclimab Studies Each Fail To Meet Primary Proptosis Responder Rate Endpoint In Thyroid Eye Disease
  Thu, Apr 2, 2026 5:08 AM

Financial data not available